Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) CEO Yvonne Greenstreet sold 1,213 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the sale, the chief executive officer now directly owns 81,526 shares in the company, valued at $20,802,989.42. The trade was a 1.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Yvonne Greenstreet also recently made the following trade(s):
- On Tuesday, November 26th, Yvonne Greenstreet sold 5,219 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62.
Alnylam Pharmaceuticals Price Performance
Shares of ALNY traded down $0.41 during mid-day trading on Friday, reaching $250.59. The stock had a trading volume of 649,260 shares, compared to its average volume of 693,578. The firm has a market cap of $32.44 billion, a price-to-earnings ratio of -115.48 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The business has a fifty day moving average of $254.04 and a 200 day moving average of $263.12. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78.
Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.
Hedge Funds Weigh In On Alnylam Pharmaceuticals
Several hedge funds have recently modified their holdings of the stock. Capital World Investors lifted its holdings in shares of Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock worth $3,906,284,000 after buying an additional 92,101 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company's stock worth $2,996,296,000 after buying an additional 98,303 shares in the last quarter. Capital Research Global Investors lifted its holdings in shares of Alnylam Pharmaceuticals by 32.9% in the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock worth $1,639,767,000 after buying an additional 1,724,610 shares in the last quarter. Regeneron Pharmaceuticals Inc. purchased a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth $1,045,822,000. Finally, T. Rowe Price Investment Management Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 39.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock worth $1,031,705,000 after buying an additional 1,245,195 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on ALNY shares. HC Wainwright reissued a "buy" rating and set a $400.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, January 13th. Barclays lifted their price target on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an "overweight" rating in a research report on Friday, November 1st. Canaccord Genuity Group lifted their price target on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a "buy" rating in a research report on Tuesday. Needham & Company LLC reaffirmed a "buy" rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, February 14th. Finally, Raymond James lifted their target price on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an "outperform" rating in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $299.48.
Check Out Our Latest Stock Analysis on ALNY
Alnylam Pharmaceuticals Company Profile
(
Get Free Report)
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Recommended Stories
Before you consider Alnylam Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.
While Alnylam Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
